ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
37.9%
116M of 307M shares
Institutional holders
151
39 new, 26 sold out
Net institutional buying
-8M
In Q2 2026
Insider trades, 12 months
9 buys · 0 sales
Net bought $2.68M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Carl L.G. Hansen | 60,740,524 | 20.60% | 13G (passive) amendment | Dec 31, 2023 |
| Baker Bros. Advisors LP | 33,012,138 | 10.80% | 13G (passive) amendment | Apr 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABCL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 33,012,138 | 10.77% | $259.15M | +2,736,200 | 1.30% |
| Capital World Investors | 13,588,349 | 4.43% | $106.67M | +227,253 | 0.01% |
| Two Sigma Investments, LP | 10,437,431 | 3.40% | $81.93M | −124,634 | 0.06% |
| TD Waterhouse Canada Inc. | 9,568,149 | 3.12% | $72.62M | +3,490 | 0.19% |
| Bank Of America Corp /De/ | 6,141,539 | 2.00% | $48.21M | +3,141,603 | 0.00% |
| UBS Asset Management Americas Inc | 4,317,206 | 1.41% | $33.89M | −3,258,270 | 0.01% |
| ArrowMark Colorado Holdings LLC | 4,105,095 | 1.34% | $32.22M | – | 1.34% |
| BlackRock, Inc. | 3,805,309 | 1.24% | $29.87M | −234,927 | 0.00% |
| Driehaus Capital Management LLC | 2,864,729 | 0.93% | $22.49M | −1,160,050 | 0.13% |
| Tudor Investment Corp Et Al | 2,063,191 | 0.67% | $16.20M | −210,298 | 0.02% |
| Marshall Wace, Llp | 1,902,191 | 0.62% | $14.93M | +1,542,508 | 0.01% |
| UBS Group AG | 1,870,633 | 0.61% | $14.68M | −2,338,419 | 0.00% |
| Morgan Stanley | 1,669,014 | 0.54% | $13.10M | −555,815 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,587,870 | 0.52% | $12.47K | New | 0.00% |
| Citadel Advisors LLC | 1,586,512 | 0.52% | $12.45M | +225,407 | 0.00% |
| National Bank Of Canada /Fi/ | 1,233,014 | 0.40% | $9.68M | +1,231,621 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 1,039,927 | 0.34% | $8.16M | New | 0.00% |
| Renaissance Technologies LLC | 990,929 | 0.32% | $7.78M | −519,700 | 0.01% |
| Counterpoint Mutual Funds LLC | 971,643 | 0.32% | $7.63M | New | 0.75% |
| State Street Corp | 731,362 | 0.24% | $5.74M | +1,149 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 151 | 116M | 37.9% | 39 / 36 | 54 / 26 | 17M | 25M |
| Q1 2026 | 138 | 124M | 40.5% | 20 / 53 | 35 / 26 | 29M | 13M |
| Q4 2025 | 144 | 109M | 35.4% | 31 / 50 | 38 / 28 | 24M | 19M |
| Q3 2025 | 142 | 104M | 34.0% | 35 / 44 | 35 / 21 | 15M | 19M |
| Q2 2025 | 128 | 108M | 35.3% | 19 / 38 | 43 / 18 | 10M | 37M |
| Q1 2025 | 129 | 136M | 44.4% | 12 / 33 | 51 / 27 | 34M | 11M |
| Q4 2024 | 146 | 114M | 37.2% | 27 / 45 | 39 / 17 | 18M | 8M |
| Q3 2024 | 139 | 106M | 34.6% | 19 / 52 | 34 / 27 | 17M | 22M |
| Q2 2024 | 148 | 115M | 37.4% | 20 / 37 | 48 / 25 | 10M | 13M |
| Q1 2024 | 154 | 122M | 39.8% | 27 / 47 | 41 / 15 | 9M | 7M |
| Q4 2023 | 143 | 120M | 39.1% | 26 / 48 | 35 / 19 | 8M | 8M |
| Q3 2023 | 138 | 120M | 39.1% | 19 / 38 | 39 / 51 | 7M | 12M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ABCL | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 13,228,596 | 4.31% | $103.84M | 0.11% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,656,204 | 0.54% | $13.00M | 0.14% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,053,900 | 0.34% | $8.27M | 0.06% | Jun 30, 2026 |
| Counterpoint Quantitative Equity ETF | 971,643 | 0.32% | $7.63M | 2.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio Developed World ex-US ETF | 564,320 | 0.18% | $4.43M | 0.01% | Jun 30, 2026 |
| iShares Genomics Immunology and Healthcare ETF | 508,935 | 0.17% | $2.91M | 1.52% | Jul 31, 2026 |
| SMALLCAP World Fund | 359,753 | 0.12% | $2.82M | 0.11% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 339,622 | 0.11% | $2.10M | 0.04% | May 29, 2026 |
| Driehaus Micro Cap Growth Fund | 246,560 | 0.08% | $1.94M | 0.32% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 180,133 | 0.06% | $1.11M | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 166,042 | 0.05% | $1.30M | 0.15% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index ETF | 134,674 | 0.04% | $830.94K | 0.01% | May 31, 2026 |
| Small Cap Value Fund | 123,712 | 0.04% | $971.14K | 0.14% | Jun 30, 2026 |
| Adara Smaller Companies Fund | 120,162 | 0.04% | $741.40K | 0.09% | May 31, 2026 |
| Avantis U.S. Equity ETF | 64,811 | 0.02% | $399.88K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carl L. G. Hansen | Chief Executive Officer, Director, 10% owner | 56,984,009 | 18.59% | Jan 5, 2026 |
| Veronique Lecault | Chief Technology Officer, Director | 9,340,044 | 3.05% | Jan 5, 2026 |
| Andrew Booth | Chief Financial Officer | 613,759 | 0.20% | Aug 14, 2026 |
| Tryn Stimart | Chief Legal Officer | 500 | 0.00% | Jan 5, 2026 |
| Michael R. Hayden | Director | 1,491,642 | 0.49% | Aug 24, 2026 |
| John S. Montalbano | Director | 256,000 | 0.08% | Aug 18, 2026 |
| Victor Sandor | Director | – | – | Jul 6, 2026 |
| Lynn Seely | Director | – | – | Jul 6, 2026 |
| Stephen Quake | Director | 1,100,436 | 0.36% | Jun 12, 2026 |
| Andrew Lo | Director | 86,938 | 0.03% | Jun 16, 2025 |
| Holdings Ltd. Thermopylae | 10% owner | 56,134,097 | 18.31% | Mar 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael R. Hayden Director | Aug 24, 2026 | Buy | +53,613 | $10.64 | $570.44K | 1,373,397 |
| John S. Montalbano Director | Aug 18, 2026 | Buy | +10,000 | $11.03 | $110.30K | 251,000 |
| Andrew Booth Chief Financial Officer | Aug 14, 2026 | Buy | +37,200 | $10.32 | $383.90K | 482,800 |
| Michael R. Hayden Director | Aug 12, 2026 | Buy | +46,387 | $10.37 | $481.03K | 1,319,784 |
| Michael R. Hayden Director | Aug 11, 2026 | Gift | −50,000 | – | – | 1,273,397 |
| Andrew Booth Chief Financial Officer | Jun 3, 2026 | Option exercise | +250,000 | $0.19 | $47.50K | 445,600 |
| John S. Montalbano Director | May 14, 2026 | Buy | +20,000 | $4.77 | $95.40K | 241,000 |
| Holdings Ltd. Thermopylae 10% owner | Feb 27, 2026 | Buy | +38,000 | $3.44 | $130.72K | 56,134,097 |
| Andrew Booth Chief Financial Officer | Feb 27, 2026 | Buy | +42,600 | $3.42 | $145.69K | 195,600 |
| Holdings Ltd. Thermopylae 10% owner | Feb 26, 2026 | Buy | +177,457 | $3.27 | $580.28K | 56,096,097 |
| Holdings Ltd. Thermopylae 10% owner | Dec 18, 2025 | Gift | −225,000 | – | – | 55,918,640 |
| John S. Montalbano Director | Nov 26, 2025 | Buy | +50,000 | $3.57 | $178.50K | 221,000 |
| Holdings Ltd. Thermopylae 10% owner | Mar 11, 2025 | Buy | +343,631 | $2.16 | $742.24K | 56,143,640 |
| John S. Montalbano Director | Mar 10, 2025 | Buy | +25,000 | $2.30 | $57.50K | 171,000 |
| John S. Montalbano Director | Mar 6, 2025 | Buy | +60,000 | $2.34 | $140.40K | 146,000 |
| Holdings Ltd. Thermopylae 10% owner | Dec 4, 2024 | Gift | −286,000 | – | – | 55,800,009 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Nov 25, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 898,000 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Sep 20, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 841,875 |
| Holdings Ltd. Thermopylae 10% owner | Aug 29, 2024 | Buy | +283,516 | $2.61 | $739.98K | 56,086,009 |
| Veronique Lecault Chief Operating Officer, Director | Jun 21, 2024 | Option exercise | +83,334 | $0.19 | $15.83K | 2,123,456 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | May 31, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 785,750 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Feb 26, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 729,625 |
| Holdings Ltd. Thermopylae 10% owner | Dec 19, 2023 | Gift | −210,000 | – | – | 55,802,493 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Nov 23, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 673,500 |
| John S. Montalbano Director | Nov 8, 2023 | Buy | +10,000 | $4.46 | $44.60K | 86,000 |
| John S. Montalbano Director | Nov 6, 2023 | Buy | +20,000 | $4.64 | $92.80K | 76,000 |
| Michael R. Hayden Director | Sep 22, 2023 | Buy | +20,000 | $4.91 | $98.20K | 1,323,397 |
| Veronique Lecault Chief Operating Officer, Director | Sep 12, 2023 | Buy | +20,000 | $5.19 | $103.80K | 2,040,122 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Aug 24, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 617,375 |
| Michael R. Hayden Director | Aug 8, 2023 | Buy | +30,000 | $5.90 | $177.00K | 1,303,397 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | May 26, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 561,250 |
| Andrew Booth Chief Financial Officer | May 26, 2023 | Buy | +14,500 | $6.85 | $99.33K | 153,000 |
| Holdings Ltd. Thermopylae 10% owner | May 26, 2023 | Buy | +153,000 | $6.52 | $997.56K | 56,012,493 |
| Veronique Lecault Chief Operating Officer, Director | May 5, 2023 | Option exercise | +250,000 | $0.19 | $47.50K | 2,020,122 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Feb 22, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 505,125 |
| Andrew Booth Chief Financial Officer | Dec 20, 2022 | Option exercise | +50,000 | $0.19 | $9.50K | 188,500 |
| Andrew Booth Chief Financial Officer | Dec 20, 2022 | Gift | −50,000 | – | – | 138,500 |
| Holdings Ltd. Thermopylae 10% owner | Dec 16, 2022 | Buy | +85,102 | $10.10 | $859.53K | 55,859,493 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Nov 18, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 449,000 |
| Holdings Ltd. Thermopylae 10% owner | Oct 31, 2022 | Gift | −70,000 | – | – | 55,774,391 |
| Holdings Ltd. Thermopylae 10% owner | Aug 19, 2022 | Buy | +200,000 | $11.46 | $2.29M | 55,844,391 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Aug 18, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 392,875 |
| Holdings Ltd. Thermopylae 10% owner | Jun 14, 2022 | Buy | +9,173 | $8.05 | $73.84K | 55,644,391 |
| Holdings Ltd. Thermopylae 10% owner | Jun 13, 2022 | Buy | +54,915 | $8.03 | $440.97K | 55,635,218 |
| Holdings Ltd. Thermopylae 10% owner | Jun 6, 2022 | Buy | +64,545 | $7.50 | $484.09K | 55,580,303 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | May 18, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 336,750 |
| Veronique Lecault Chief Operating Officer, Director | May 16, 2022 | Buy | +200,000 | $6.34 | $1.27M | 1,770,122 |
| Holdings Ltd. Thermopylae 10% owner | May 13, 2022 | Buy | +300,000 | $7.26 | $2.18M | 55,515,758 |
| Andrew Booth Chief Financial Officer | May 12, 2022 | Buy | +85,000 | $5.79 | $492.15K | 138,500 |
| Holdings Ltd. Thermopylae 10% owner | May 12, 2022 | Buy | +1,408,468 | $6.41 | $9.03M | 55,215,758 |
| John S. Montalbano Director | Mar 4, 2022 | Buy | +10,000 | $8.54 | $85.40K | 56,000 |
| John S. Montalbano Director | Mar 1, 2022 | Buy | +20,000 | $9.05 | $181.00K | 46,000 |
| Veronique Lecault Chief Operating Officer, Director | Feb 28, 2022 | Buy | +230,789 | $8.66 | $2.00M | 1,570,122 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Feb 22, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 280,625 |
| Andrew Booth Chief Financial Officer | Dec 10, 2021 | Gift | −500,000 | – | – | 53,500 |
| Andrew Booth Chief Financial Officer | Dec 10, 2021 | Option exercise | +500,000 | $0.32 | $160.00K | 553,500 |
| Veronique Lecault Chief Operating Officer, Director | Dec 8, 2021 | Gift | −250,000 | – | – | 1,339,333 |
| Veronique Lecault Chief Operating Officer, Director | Dec 8, 2021 | Option exercise | +250,000 | $0.19 | $47.50K | 1,589,333 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Dec 7, 2021 | Gift | −750,000 | – | – | 53,807,290 |
| Holdings Ltd. Thermopylae 10% owner | Dec 7, 2021 | Gift | −750,000 | – | – | 53,807,290 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.